New-onset atrial fibrillation and acute coronary syndrome

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 7, 2010, Pages 941-948

  Lau, Dennis H ^a   Alasady, Muayad ^a   Brooks, Anthony G ^a   Sanders, Prashanthan ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

acute coronary syndrome; antiarrhythmic drugs; atrial fibrillation; oral anticoagulation

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; DRONEDARONE; FIBRINOLYTIC AGENT; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROCAINAMIDE; SOTALOL; TRANDOLAPRIL; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; CARDIOVERSION; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; REVIEW; STROKE; TREND STUDY; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; ATRIAL FIBRILLATION; COMPLICATION; ORAL DRUG ADMINISTRATION;

ACUTE CORONARY SYNDROME; ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; INCIDENCE;

EID: 77954516058     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.61     Document Type: Review

References (68)

1. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am. J. Med. 98, 476-484 (1995).
2. Cristal N, Szwarcberg J, Gueron M. Supraventricular arrhythmias in acute myocardial infarction. Prognostic importance of clinical setting; mechanism of production. Ann. Intern. Med. 82, 35-39 (1975).
3. Hunt D, Sloman G, Penington C. Effects of atrial fibrillation on prognosis of acute myocardial infarction. Br. Heart J. 40, 303-307 (1978).
4. Behar S, Zahavi Z, Goldbourt U, Reicher- Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. Eur. Heart J. 13, 45-50 (1992).
5. Sakata K, Kurihara H, Iwamori K et al. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. Am. J. Cardiol. 80, 1522-1527 (1997). (Pubitemid 28011823)
6. Crenshaw BS, Ward SR, Granger CB et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J. Am. Coll. Cardiol. 30, 406-413 (1997).
7. Wong CK, White HD, Wilcox RG et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am. Heart J. 140, 878-885 (2000).
8. Rathore SS, Berger AK, Weinfurt KP et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 101, 969-974 (2000).
9. Pizzetti F, Turazza FM, Franzosi MG et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 86, 527-532 (2001).
10. Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. Am. Heart J. 143, 519-527 (2002).
11. Asanin M, Perunicic J, Mrdovic I et al. Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. Eur. J. Heart Fail. 7, 671-676 (2005).
12. Kober L, Swedberg K, McMurray JJ et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur. J. Heart Fail. 8, 591-598 (2006).
13. Saczynski JS, McManus D, Zhou Z et al. Trends in atrial fibrillation complicating acute myocardial infarction. Am. J. Cardiol. 104, 169-174 (2009).
14. Mehta RH, Dabbous OH, Granger CB et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am. J. Cardiol. 92, 1031-1036 (2003).
15. Lau DH, Huynh LT, Chew DP et al. Prognostic impact of types of atrial fibrillation in acute coronary syndromes. Am. J. Cardiol. 104, 1317-1323 (2009).
16. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. Trandolapril Cardiac Evaluation. Eur. Heart J. 20, 748-754 (1999).
17. Eldar M, Canetti M, Rotstein Z et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 97, 965-970 (1998).
18. Aronson D, Boulos M, Suleiman A et al. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction. Am. J. Cardiol. 100, 753-757 (2007).
19. Hwang HJ, Ha JW, Joung B et al. Relation of inflammation and left atrial remodeling in atrial fibrillation occurring in early phase of acute myocardial infarction. Int. J. Cardiol. DOI: 10.1016/j. ijcard.2009.05.065 (2009) (Epub ahead of print).
20. Siu CW, Jim MH, Ho HH et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest 132, 44-49 (2007).
21. Asanin MR, Vasiljevic ZM, Matic MD et al. The long-term risk of stroke in patients with acute myocardial infarction complicated with new-onset atrial fibrillation. Clin. Cardiol. 32, 467-470 (2009).
22. Asanin M, Vasiljevic Z, Matic M et al. Outcome of patients in relation to duration of new-onset atrial fibrillation following acute myocardial infarction. Cardiology 107, 197-202 (2007).
23. Sinno H, Derakhchan K, Libersan D et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107, 1930-1936 (2003).
24. Nielsen FE, Andersen HH, Gram-Hansen P, Sorensen HT, Klausen IC. The relationship between ECG signs of atrial infarction and the development of supraventricular arrhythmias in patients with acute myocardial infarction. Am. Heart J. 123, 69-72 (1992).
25. Shakir DK, Arafa SO. Right atrial infarction, atrial arrhythmia and inferior myocardial infarction form a missed triad: a case report and review of the literature. Can. J. Cardiol. 23, 995-997 (2007).
26. Sanders P, Morton JB, Davidson NC et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation 108, 1461-1468 (2003).
27. Rechavia E, Strasberg B, Mager A et al. The incidence of atrial arrhythmias during inferior wall myocardial infarction with and without right ventricular involvement. Am. Heart J. 124, 387-391 (1992).
28. Sugiura T, Iwasaka T, Takahashi N et al. Factors associated with atrial fibrillation in Q wave anterior myocardial infarction. Am. Heart J. 121, 1409-1412 (1991).
29. Tofler GH, Muller JE, Stone PH et al. Pericarditis in acute myocardial infarction: characterization and clinical significance. Am. Heart J. 117, 86-92 (1989).
30. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 96, 1686-1695 (1997).
31. Olgin JE, Sih HJ, Hanish S et al. Heterogeneous atrial denervation creates substrate for sustained atrial fibrillation. Circulation 98, 2608-2614 (1998).
32. Satoh T, Zipes DP. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J. Cardiovasc. Electrophysiol. 7, 833-842 (1996).
33. Wichmann J, Ertl G, Rudolph G, Kochsiek K. Effect of experimentally induced atrial fibrillation on coronary circulation in dogs. Basic Res. Cardiol. 78, 473-491 (1983).
34. White CW, Holida MD, Marcus ML. Effects of acute atrial fibrillation on the vasodilator reserve of the canine atrium. Cardiovasc. Res. 20, 683-689 (1986).
35. Kochiadakis GE, Skalidis EI, Kalebubas MD et al. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur. Heart J. 23, 734-741 (2002).
36. Ariyarajah V, Malinski M, Khadem A et al. Relation of recurrence of atrial fibrillation after non-ST-elevation acute myocardial infarction to left atrial abnormality. Am. J. Cardiol. 101, 30-34 (2008).
37. Asanin M, Perunicic J, Mrdovic I et al. Significance of recurrences of new atrial fibrillation in acute myocardial infarction. Int. J. Cardiol. 109, 235-240 (2006).
38. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367, 1903-1912 (2006).
39. Stenestrand U, Lindback J, Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Circulation 112, 3225-3231 (2005).
40. Depta JP, Cannon CP, Fonarow GC et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am. J. Cardiol. 104, 1171-1178 (2009).
41. Wang TY, Robinson LA, Ou FS et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am. Heart J. 155, 361-368 (2008).
42. Rubboli A, Colletta M, Sangiorgio P, Di Pasquale G. Antithrombotic treatment after coronary artery stenting in patients on chronic oral anticoagulation: an international survey of current clinical practice. Ital. Heart J. 5, 851-856 (2004).
43. Sourgounis A, Lipiecki J, Lo TS, Hamon M. Coronary stents and chronic anticoagulation. Circulation 119, 1682-1688 (2009).
44. Rossini R, Musumeci G, Lettieri C et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am. J. Cardiol. 102, 1618-1623 (2008).
45. Karjalainen PP, Porela P, Ylitalo A et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur. Heart J. 28, 726-732 (2007).
46. Holmes DR Jr, Kereiakes DJ, Kleiman NS et al. Combining antiplatelet and anticoagulant therapies. J. Am. Coll. Cardiol. 54, 95-109 (2009).
47. Rubboli A, Halperin JL, Airaksinen KE et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann. Med. 40, 428-436 (2008).
48. Zinn A, Feit F. Optimizing antithrombotic strategies in patients with concomitant indications for warfarin undergoing coronary artery stenting. Am. J. Cardiol. 104, 49C-54C (2009).
49. Lip GY, Huber K, Andreotti F et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb. Haemost. 103, 13-28 (2010).
50. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347, 1825-1833 (2002).
51. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356, 1789-1794 (2000).
52. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834-1840 (2002).
53. Corley SD, Epstein AE, DiMarco JP et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109, 1509-1513 (2004).
54. Wong CK, White HD, Wilcox RG et al. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. Heart 88, 357-362 (2002).
55. Kilborn MJ, Rathore SS, Gersh BJ, Oetgen WJ, Solomon AJ. Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation. Am. Heart J. 144, 1095-1101 (2002).
56. Kontoyannis DA, Anastasiou-Nana MI, Kontoyannis SA, Zaga AK, Nanas JN. Intravenous amiodarone decreases the duration of atrial fibrillation associated with acute myocardial infarction. Cardiovasc. Drugs Ther. 15, 155-160 (2001).
57. Julian DG, Camm AJ, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349, 667-674 (1997).
58. Singh D, Cingolani E, Diamond GA, Kaul S. Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? J. Am. Coll. Cardiol. 55, 1569-1576 (2010).
59. Kober L, Bloch Thomsen PE, Moller M et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356, 2052-2058 (2000).
60. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324, 781-788 (1991).
61. McMurray J, Kober L, Robertson M et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J. Am. Coll. Cardiol. 45, 525-530 (2005).
62. McCullough PA, Sandberg KR, Borzak S et al. Benefits of aspirin and b-blockade after myocardial infarction in patients with chronic kidney disease. Am. Heart. J. 144, 226-232 (2002).
63. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100, 376-380 (1999).
64. Fauchier L, Pierre B, de Labriolle A et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 51, 828-835 (2008).
65. Sakabe M, Shiroshita-Takeshita A, Maguy A et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 116, 2101-2109 (2007).
66. Laurent G, Moe G, Hu X et al. Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model. Cardiovasc. Res. 77, 89-97 (2008).
67. Mozaffarian D, Psaty BM, Rimm EB et al. Fish intake and risk of incident atrial fibrillation. Circulation 110, 368-373 (2004).
68. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 120, 2315-2321 (2009).